Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:IBIO NASDAQ:RLYB NASDAQ:TELO NASDAQ:VYNE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIBIOiBio$1.68-4.2%$1.71$0.56▼$3.82$83.41M1.261.33 million shs406,796 shsRLYBRallybio$15.75-1.2%$14.29$2.59▼$17.57$83.26M-0.9189,944 shs10,437 shsTELOTelomir Pharmaceuticals$1.32+1.5%$1.30$1.05▼$3.10$90.79M-0.25136,129 shs38,029 shsVYNEVYNE Therapeutics$0.68-0.6%$0.66$0.28▼$1.60$22.58M2259,289 shs476,984 shsThe 7 Hottest IPO Stories of 2026MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIBIOiBio0.00%+8.02%-7.41%-11.62%+174,999,900.00%RLYBRallybio-0.38%+0.13%-5.51%+89.09%+503.24%TELOTelomir Pharmaceuticals+1.56%+5.69%+4.00%+2.36%+2.36%VYNEVYNE Therapeutics+4.66%+4.67%-0.26%+13.31%-61.53%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIBIOiBio$1.68-4.2%$1.71$0.56▼$3.82$83.41M1.261.33 million shs406,796 shsRLYBRallybio$15.75-1.2%$14.29$2.59▼$17.57$83.26M-0.9189,944 shs10,437 shsTELOTelomir Pharmaceuticals$1.32+1.5%$1.30$1.05▼$3.10$90.79M-0.25136,129 shs38,029 shsVYNEVYNE Therapeutics$0.68-0.6%$0.66$0.28▼$1.60$22.58M2259,289 shs476,984 shsThe 7 Hottest IPO Stories of 2026MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIBIOiBio0.00%+8.02%-7.41%-11.62%+174,999,900.00%RLYBRallybio-0.38%+0.13%-5.51%+89.09%+503.24%TELOTelomir Pharmaceuticals+1.56%+5.69%+4.00%+2.36%+2.36%VYNEVYNE Therapeutics+4.66%+4.67%-0.26%+13.31%-61.53%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceIBIOiBio 3.13Buy$5.00185.71% UpsideRLYBRallybio 1.00SellN/AN/ATELOTelomir Pharmaceuticals 2.00HoldN/AN/AVYNEVYNE Therapeutics 1.75ReduceN/AN/ACurrent Analyst Ratings BreakdownLatest VYNE, TELO, IBIO, and RLYB Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/2/2026IBIOiBio Chardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$5.006/24/2026IBIOiBio Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)6/8/2026IBIOiBio Raymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$5.006/8/2026IBIOiBio Raymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$5.006/5/2026IBIOiBio B. Riley FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$6.005/8/2026RLYBRallybio Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)5/4/2026VYNEVYNE Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/21/2026TELOTelomir Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/9/2026IBIOiBio Chardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$5.00(Data available from 7/2/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookIBIOiBio$300K289.79N/AN/A$0.90 per share1.94RLYBRallybio$860K98.23N/AN/A$10.98 per share1.45TELOTelomir PharmaceuticalsN/AN/AN/AN/A$0.17 per shareN/AVYNEVYNE Therapeutics$570K39.84N/AN/A$0.83 per share0.82Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateIBIOiBio-$18.38M-$0.58N/AN/AN/AN/A-53.86%-46.48%9/4/2026 (Estimated)RLYBRallybio-$8.98M-$4.34N/AN/AN/A-911.07%-55.79%-51.48%8/6/2026 (Estimated)TELOTelomir Pharmaceuticals-$10.41M-$0.29N/AN/AN/AN/A-201.23%-172.71%9/2/2026 (Estimated)VYNEVYNE Therapeutics-$26.48M-$0.38N/AN/AN/A-4,726.21%-70.42%-63.46%8/13/2026 (Estimated)Latest VYNE, TELO, IBIO, and RLYB EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2026Q1 2026VYNEVYNE Therapeutics-$0.18-$0.08+$0.10-$0.08$0.20 million$0.09 million5/14/2026Q1 2026TELOTelomir Pharmaceuticals-$0.07-$0.03+$0.04-$0.03N/AN/A5/13/2026Q1 2026RLYBRallybio-$1.20-$1.46-$0.26-$1.46$0.21 million$0.21 million5/12/2026Q3 2026IBIOiBio-$0.06-$0.07-$0.01-$0.06$0.02 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthIBIOiBioN/AN/AN/AN/AN/ARLYBRallybioN/AN/AN/AN/AN/ATELOTelomir PharmaceuticalsN/AN/AN/AN/AN/AVYNEVYNE TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioIBIOiBioN/A11.8811.88RLYBRallybioN/A12.9212.92TELOTelomir PharmaceuticalsN/A7.007.00VYNEVYNE TherapeuticsN/A20.8620.86Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipIBIOiBio7.90%RLYBRallybio90.34%TELOTelomir PharmaceuticalsN/AVYNEVYNE Therapeutics83.78%Insider OwnershipCompanyInsider OwnershipIBIOiBio2.75%RLYBRallybio10.30%TELOTelomir PharmaceuticalsN/AVYNEVYNE Therapeutics3.03%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableIBIOiBio10049.68 million48.31 millionN/ARLYBRallybio405.30 million4.75 millionNot OptionableTELOTelomir Pharmaceuticals168.78 millionN/AN/AVYNEVYNE Therapeutics3033.35 million32.34 millionNot OptionableVYNE, TELO, IBIO, and RLYB HeadlinesRecent News About These CompaniesVYNE Therapeutics Insider Trading Activity | NASDAQ:VYNE | BenzingaJuly 1 at 1:29 PM | benzinga.comVYNE Therapeutics (VYNE) price target decreased by 38.46% to 2.04May 15, 2026 | msn.comShareholder Alert: The Ademi Firm investigates whether VYNE Therapeutics Inc. is obtaining a Fair Price for its Public ShareholdersDecember 18, 2025 | prnewswire.com3 penny stocks to watch now, 12/18/25December 18, 2025 | msn.comVYNE to merge with Yarrow in $200 million dealDecember 18, 2025 | thepharmaletter.comTRoundup: Harbor BioMed Announces Collaboration and License Agreement with Bristol Myers, Squibb, VYNE Therapeutics Enters Merger Agreement with Yarrow BioscienceDecember 17, 2025 | pharmexec.comP$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of VYNE Therapeutics Inc. (NASDAQ: VYNE)December 17, 2025 | prnewswire.comVYNE Stock Alert: Halper Sadeh LLC is Investigating Whether the Merger of VYNE Therapeutics Inc. is Fair to ShareholdersDecember 17, 2025 | businesswire.comVYNE Therapeutics Inc. (VYNE) Yarrow Bioscience, Inc. - M&A Call Prepared Remarks TranscriptDecember 17, 2025 | seekingalpha.comVyne Therapeutics stock soars after merger with Yarrow BioscienceDecember 17, 2025 | za.investing.comVyne Therapeutics, Yarrow Bioscience to MergeDecember 17, 2025 | marketwatch.comVyne Therapeutics shares surge on merger deal with Yarrow BioscienceDecember 17, 2025 | msn.comVYNE Therapeutics and Yarrow Bioscience Announce Merger AgreementDecember 17, 2025 | globenewswire.comVYNE Therapeutics Approves Director Elections and ProposalsDecember 12, 2025 | tipranks.comVYNE Therapeutics reports Q3 EPS (17c) vs (29c) last yearNovember 6, 2025 | msn.comVYNE Therapeutics Inc. (VYNE) Reports Q3 Loss, Tops Revenue EstimatesNovember 6, 2025 | zacks.comVYNE Therapeutics Reports 2025 Third Quarter Financial Results and Provides Business UpdateNovember 6, 2025 | globenewswire.comIncyte scraps BET inhibitor against backdrop of safety concerns for the drug classOctober 28, 2025 | fiercebiotech.comFVYNE Therapeutics (VYNE) Price Target Decreased by 22.00% to 3.32October 1, 2025 | msn.comVYNE Therapeutics Faces Nasdaq Non-Compliance NoticeSeptember 12, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeVYNE, TELO, IBIO, and RLYB Company DescriptionsiBio NASDAQ:IBIO$1.68 -0.07 (-4.23%) As of 01:20 PM Eastern This is a fair market value price provided by Massive. Learn more.iBio, Inc., a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States. The company operates in two segments: Biopharmaceuticals and Bioprocessing. Its lead therapeutic candidate is IBIO-100 that is being advanced for investigational new drug development for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis. The company is also developing vaccine candidates comprising IBIO-200 and IBIO-201, which are in preclinical development for the prevention of severe acute respiratory syndrome coronavirus 2; and IBIO-400 for the treatment of classical swine fever. In addition, it is developing recombinant proteins for third parties on a catalog and custom basis; and offers a range of process development, manufacturing, filling and finishing, and bio analytic services. iBio, Inc. has a license agreement with Planet Biotechnology, Inc. to develop therapeutics for infectious diseases; collaboration agreement with The Texas A&M University System for the development of coronavirus disease 2019 vaccine candidates; license agreement with the University of Natural Resources and Life Sciences, Vienna; and collaboration agreement with CC-Pharming Ltd. The company is headquartered in Bryan, Texas.Rallybio NASDAQ:RLYB$15.75 -0.19 (-1.17%) As of 01:20 PM Eastern This is a fair market value price provided by Massive. Learn more.Rallybio Corporation, a clinical-stage biotechnology company, engages in development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that has completed Phase I clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT); and RLYB211 for the prevention of FNAIT. The company is also developing RLYB114, a pegylated complement factor 5 (C5)-targeted Affibody molecule in preclinical development for the treatment of complement-mediated ophthalmic diseases; RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB331, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload. It entered into a strategic alliance with AbCellera to discover, develop, and commercialize novel antibody-based therapeutics for rare diseases. Rallybio has collaboration with Exscientia for the development of small molecule therapeutics for rare diseases; and collaboration agreement with Johnson & Johnson to provide pregnant individuals therapeutic solutions at risk of fetal and neonatal alloimmune thrombocytopenia. The company was founded in 2018 and is headquartered in New Haven, Connecticut.Telomir Pharmaceuticals NASDAQ:TELO$1.32 +0.02 (+1.54%) As of 01:17 PM Eastern This is a fair market value price provided by Massive. Learn more.Telomir Pharmaceuticals, Inc., a pre-clinical-stage pharmaceutical company, focuses on the development and commercialization of therapeutic treatment for human stem cells. The company develops TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic intervention against age-related inflammatory conditions, such as hemochromatosis and osteoarthritis, as well as for post-chemotherapy health problems. The company was formerly known as Metallo Therapies Inc. and changed its name to Telomir Pharmaceuticals, Inc. in October 2022. Telomir Pharmaceuticals, Inc. was incorporated in 2021 and is headquartered in Baltimore, Maryland.VYNE Therapeutics NASDAQ:VYNE$0.68 0.00 (-0.59%) As of 01:18 PM Eastern This is a fair market value price provided by Massive. Learn more.VYNE Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing proprietary and therapeutics for the treatment of immuno-inflammatory conditions. The company's lead product is VYN201, a locally administered pan- bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways with low systemic exposure. It also develops VYN202, a BD2-selective oral small molecule BET inhibitor for the treatment of immuno-inflammatory indications. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Meta’s AI Compute Push Could Turn Its Massive CapEx Bill Into a Competitive Weapon SanDisk’s Volatility May Be Telling Bulls What They Want to Hear SMRs Spark a Chain Reaction for Nano Nuclear 3 Dividend ETFs Built for Stability in a Volatile Market Agility Robotics’ SPAC Deal Opens a Rare Door Into Humanoid AI Netflix Stock Is Near 2021 Levels, and Bulls See 4 Reasons to Care General Mills Is a 5-Star Turnaround Play for Buy and Hold Investors Tesla Stock Surges 15% as FSD Update Backs Its Autonomy Thesis Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
